Eiger BioPharmaceuticals, Inc.
(NASDAQ : CLDN)

( )
CLDN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.29%300.261.4%$596.56m
AMGNAmgen, Inc.
0.15%233.771.3%$511.86m
GILDGilead Sciences, Inc.
1.74%67.081.0%$364.16m
REGNRegeneron Pharmaceuticals, Inc.
1.06%372.262.6%$296.10m
VRTXVertex Pharmaceuticals, Inc.
0.08%223.251.9%$267.50m
ILMNIllumina, Inc.
2.08%326.473.5%$239.80m
ALXNAlexion Pharmaceuticals, Inc.
6.02%113.892.0%$195.68m
ARWRArrowhead Pharmaceuticals, Inc.
2.66%67.2712.0%$195.66m
EXASEXACT Sciences Corp.
3.15%86.2424.0%$182.79m
CLVSClovis Oncology, Inc.
8.47%9.6114.7%$181.81m
SRPTSarepta Therapeutics, Inc.
-0.46%109.4614.6%$145.45m
AAgilent Technologies, Inc.
0.88%82.251.6%$143.48m
NBIXNeurocrine Biosciences, Inc.
0.28%116.815.0%$128.05m
BMRNBioMarin Pharmaceutical, Inc.
-0.20%79.924.3%$126.79m
SGENSeattle Genetics, Inc.
0.29%117.506.1%$126.10m

Company Profile

Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.